Six brokers set USD 6.33 target for MacroGenics stock

Published on 10/17/2026 at 21:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The 52-week range is USD 1.29 to USD 5.08. MacroGenics stock last traded at USD 3.25 on October 16, down 3.56 percent versus the Nasdaq prior close of USD 3.37.

Six Brokerages Set a Target

Six brokerages assigned a USD 6.33 average target on October 17, 2026.
The 52-week range was USD 1.29 to USD 5.08 on October 16, 2026.
MacroGenics stock last traded at USD 3.25 on October 16, 2026 at 4:00 p.m. ET, down 3.56 percent versus the Nasdaq prior close of USD 3.37.
The next estimated earnings date is November 11, 2026.

MGNX, US5560991094, Illustration mit AI erstellt.

Six brokerages assigned MacroGenics an average 12-month target of USD 6.33 on October 17, 2026, putting the target 94.77 percent above the last Nasdaq price of USD 3.25. MarketBeat reported one sell, three hold and two buy ratings among the six firms. The last Nasdaq price was USD 3.25 on October 16, 2026 at 4:00 p.m. ET, down 3.56 percent versus the Nasdaq prior close of USD 3.37.

Range and recent trading

MacroGenics opened at USD 3.25 on October 16, 2026 and traded between a day low of USD 3.23 and a day high of USD 3.45. Volume reached 347,492 shares, below the average volume of 583,653 shares. The 52-week range was USD 1.29 to USD 5.08, leaving the last price 36.02 percent below the high and 151.94 percent above the low.

Valuation and reporting date

Market capitalization stood at USD 207.0 million on October 16, 2026, while the trailing P/E ratio was minus 14.77. MacroGenics describes its business as the development of antibody-based cancer therapies, including antibody-drug conjugates and bispecific antibodies, according to MacroGenics. The next estimated earnings date is November 11, 2026, according to MarketBeat.

MarketBeat also reported that B. Riley raised its target from USD 9.00 to USD 11.00 on August 17, 2026, while maintaining a buy rating.

Comparison with peers

MGNX (Nasdaq, USD): minus 3.56 percent, P/E minus 14.77, market capitalization USD 207.0 million.
Immunocore (Nasdaq, USD): minus 0.27 percent, P/E minus 154.49, market capitalization USD 1.5 billion.
Sutro Biopharma (Nasdaq, USD): minus 4.54 percent, P/E minus 0.63, market capitalization USD 181.4 million.

What the range signals

The stock finished 36.02 percent below its 52-week high, while the peer comparison shows a weaker daily move than Sutro Biopharma but a sharper decline than Immunocore. The average target of USD 6.33 is a separate valuation reference from the trading range, not a forecast by this article.

MacroGenics was last at USD 3.25 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 3.56 percent versus the Nasdaq prior close of USD 3.37.